StocksMedium•16 October 2026•
1 min read
FDA Approves Roche's Enspryng for Thyroid Eye Disease Treatment
Key Facts
1Roche's drug Enspryng has received FDA approval for the treatment of thyroid eye disease.
The U.S. Food and Drug Administration (FDA) has approved Roche's drug Enspryng for the treatment of thyroid eye disease in adults. Seeking Alpha reported that the medication, developed by Roche Group's Genentech, represents the first and only at-home subcutaneous treatment option for the condition.
The approval follows a review of clinical data demonstrating the drug's efficacy and expanding its therapeutic reach. Regarding market performance, RHHVF closed at $457.03 on October 15, 2026, having reached a day high of $460 and a low of $448.27 during that session.